AB-PN561 PCYT1A-pS329+pS331 Antibody

Phosphosite-specific polyclonal antibody for monitoring the phosphorylation of human PCYT1A; CTPCT; CCTA



Address: 8755 Ash Street, Suite 1 Vancouver, British Columbia, Canada V6P 6T3

Email: info@kinexus.ca Phone: 604-323-2547

Target Protein	
Name Long:	CTP: phosphocholine cytidylyltransferase isoform A
Alias:	CCT A; CCT-alpha; CCTA; Choline-phosphate cytidylyltransferase A; CT; CT A; CTA; CTP:phosphocholine cytidylyltransferase A; CTPCT; PCY1A; PCYT1; PCYT1A; phosphate cytidylyltransferase 1, choline, alpha; Phosphorylcholine transferase A
UniProt ID:	P49585
Sequence Predicted Mass (KDa):	41.731 (367 AA; P49585)
Observed SDS-PAGE Mass (KDa):	40-45
Immunogen	
Antibody Immunogen Source:	Human PCYT1A; CTPCT; CCTA sequence peptide
Antibody Immunogen Sequence:	TRER(pS)P(pS)PSF(bA)C (bA) = beta-alanine
Location in Target:	Corresponds to amino acid residues T325 to F334; Near the C-terminus of the protein. These are among the main in vivo phosphorylation sites in PCYT1A.
Peptide Type:	For phosphosite-specific recognition of target.
Target Phosphosite:	Ser-329+Ser-331
Production Antibody Host Species:	Rabbit
Antibody Type:	Polyclonal
Antibody Ig Isotype Clone Lot:	Immunoglobulin G
Production Method:	The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.This antibody was also subject to negative purification over phosphotyrosine-agarose.
Production Method: Antibody Amount:	peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris. This antibody was also subject to negative purification
	peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris. This antibody was also subject to negative purification over phosphotyrosine-agarose.
Antibody Amount:	 peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris. This antibody was also subject to negative purification over phosphotyrosine-agarose. 25 μg
Antibody Amount: Antibody Concentration:	 peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris. This antibody was also subject to negative purification over phosphotyrosine-agarose. 25 μg

AB-PN561 PCYT1A-pS329+pS331 Antibody



Address: 8755 Ash Street, Suite 1 Vancouver, British Columbia, Canada V6P 6T3

Email: info@kinexus.ca Phone: 604-323-2547

Applications	
Product Use:	Western blotting Antibody microarrays
Antibody Dilution Recommended:	2 µg/ml for immunoblotting
Antibody Species Reactivity:	Human, mouse, rat and many other mammals

This product is for in vitro research use only and is not intended for use in humans or animals.

For more information on our products please visit <u>www.kinexusproducts.ca</u> or contact us at 1-866-KINEXUS(546-3987)